Seikagaku
As of the edition of 20 October 2026, Seikagaku runs 4 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Went quiet | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Condoliase | none listed | 0 |
| Diclofenac etalhyaluronate | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Eye: 2 trials led
- Bones, joints and muscles: 1 trials led
- Nervous system: 1 trials led